Literature DB >> 31672181

Risk of Mortality Following Catheter Ablation of Atrial Fibrillation.

Edward P Cheng1, Christopher F Liu1, Ilhwan Yeo2, Steven M Markowitz1, George Thomas1, James E Ip1, Luke K Kim1, Bruce B Lerman1, Jim W Cheung3.   

Abstract

BACKGROUND: Although procedure-related deaths during index admission following catheter ablation of AF have been reported to be low, adverse outcomes can occur after discharge. There are limited data on mortality early after AF ablation.
OBJECTIVES: This study aimed to identify rates, trends, and predictors of early mortality post-atrial fibrillation (AF) ablation.
METHODS: Using the all-payer, nationally representative Nationwide Readmissions Database, we evaluated 60,203 admissions of patients 18 years of age or older for AF ablation between 2010 and 2015. Early mortality was defined as death during initial admission or 30-day readmission. Based on International Classification of Diseases-9th Revision, Clinical Modification codes, we identified comorbidities, procedural complications, and causes of readmission following AF ablation. Multivariable logistic regression was performed to assess predictors of early mortality.
RESULTS: Early mortality following AF ablation occurred in 0.46% cases, with 54.3% of deaths occurring during readmission. From 2010 to 2015, quarterly rates of early mortality post-ablation increased from 0.25% to 1.35% (p < 0.001). Median time from ablation to death was 11.6 (interquartile range [IQR]: 4.2 to 22.7) days. After adjustment for age and comorbidities, procedural complications (adjusted odds ratio [aOR]: 4.06; p < 0.001), congestive heart failure (CHF) (aOR: 2.20; p = 0.011) and low AF ablation hospital volume (aOR: 2.35; p = 0.003) were associated with early mortality. Complications due to cardiac perforation (aOR: 2.98; p = 0.007), other cardiac (aOR: 12.8; p < 0.001), and neurologic etiologies (aOR: 8.72; p < 0.001) were also associated with early mortality.
CONCLUSIONS: In a nationally representative cohort, early mortality following AF ablation affected nearly 1 in 200 patients, with the majority of deaths occurring during 30-day readmission. Procedural complications, congestive heart failure, and low hospital AF ablation volume were predictors of early mortality. Prompt management of post-procedure complications and CHF may be critical for reducing mortality rates following AF ablation.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atrial fibrillation; catheter ablation; early mortality; outcomes

Mesh:

Year:  2019        PMID: 31672181     DOI: 10.1016/j.jacc.2019.08.1036

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

Review 1.  Catheter Ablation of Atrial Fibrillation in Heart Failure: from Evidences to Guidelines.

Authors:  Arianna Cirasa; Carmelo La Greca; Domenico Pecora
Journal:  Curr Heart Fail Rep       Date:  2021-04-04

2.  Catheter ablation for atrial fibrillation in a low-volume center using contemporary technology.

Authors:  Julian Cheong Kiat Tay; Xinzhe James Cai; Jing Lin; Shufen Liang; Ai Ling Him; Sherida Binte Syed Hamid; Kelvin Cheok Keng Wong; Colin Yeo; Vern Hsen Tan
Journal:  Int J Cardiol Heart Vasc       Date:  2020-10-23

3.  Preprocedure Application of Machine Learning and Mechanistic Simulations Predicts Likelihood of Paroxysmal Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation.

Authors:  Julie K Shade; Rheeda L Ali; Dante Basile; Dan Popescu; Tauseef Akhtar; Joseph E Marine; David D Spragg; Hugh Calkins; Natalia A Trayanova
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-06-14

4.  Catheter Ablation for Hospitalized Atrial Fibrillation Patients with Reduced Systolic Function: Analysis of Inpatient Mortality, Resource Utilization and Complications.

Authors:  Muhammad Bilal Munir; Muhammad Zia Khan; Pratik Agrawal; Zain Ul Abideen Asad; Moinuddin Syed; Kinjan Patel; BilYasir Abdul Ghaffarlal; Muhammad U Khan; Safi U Khan; Sudarshan Balla; Jonathan C Hsu
Journal:  J Atr Fibrillation       Date:  2021-02-28

5.  Institutional Variation in 30-Day Complications Following Catheter Ablation of Atrial Fibrillation.

Authors:  Linh Ngo; Anna Ali; Anand Ganesan; Richard Woodman; Harlan M Krumholz; Robert Adams; Isuru Ranasinghe
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

6.  A multicenter study comparing the outcome of catheter ablation of atrial fibrillation between cryoballoon and radiofrequency ablation in patients with heart failure (CRABL-HF): Study design.

Authors:  Koji Miyamoto; Kanae Hasegawa; Hiroki Takahashi; Yoh Masue; Naoya Kataoka; Koji Fukuzawa; Keiichi Ashikaga; Takashi Noda; Kazuhiro Satomi; Hiroshi Tada; Masahiko Takagi; Satoshi Yasuda; Kengo Kusano
Journal:  J Arrhythm       Date:  2020-03-15

Review 7.  Efficacy and safety of same-day discharge after atrial fibrillation ablation: A systematic review and meta-analysis.

Authors:  Sina Rashedi; Hamed Tavolinejad; Sina Kazemian; Mahta Mardani; Maryam Masoudi; Farzad Masoudkabir; Majid Haghjoo
Journal:  Clin Cardiol       Date:  2022-01-27       Impact factor: 2.882

8.  Sleep apnea in atrial fibrillation - Highly prevalent, highly relevant, but most patients are not somnolent!

Authors:  Kadhim Kadhim; Dennis H Lau; Prashanthan Sanders; Dominik Linz
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-06

9.  Ablation for paroxysmal atrial fibrillation-real-life results from a middle-volume electrophysiology laboratory.

Authors:  Piotr Kulakowski; Agnieszka Sikorska; Roman Piotrowski; Tomasz Kryński; Jakub Baran
Journal:  J Interv Card Electrophysiol       Date:  2021-01-09       Impact factor: 1.900

10.  Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation.

Authors:  Stijn P G van Vugt; Sjoerd W Westra; Rick H J A Volleberg; Gerjon Hannink; Rena Nakamura; Carlo de Asmundis; Gian-Battista Chierchia; Eliano P Navarese; Marc A Brouwer
Journal:  Europace       Date:  2021-12-07       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.